Elsevier

Biomaterials

Volume 114, January 2017, Pages 71-81
Biomaterials

Local release of dexamethasone from macroporous scaffolds accelerates islet transplant engraftment by promotion of anti-inflammatory M2 macrophages

https://doi.org/10.1016/j.biomaterials.2016.11.004Get rights and content

Abstract

Transplant-associated inflammatory responses generate an unfavorable microenvironment for tissue engraftment, particularly for cells susceptible to inflammatory stress, such as pancreatic islets. The localized delivery of anti-inflammatory agents, such as glucocorticoids, offers a promising approach to minimize the detrimental side effects associated with systemic delivery; however, the dosage must be carefully tailored to avoid deleterious responses, such as poor engraftment. Herein, we employed a polydimethylsiloxane (PDMS)-based three-dimensional scaffold platform for the local and controlled delivery of dexamethasone (Dex). Incorporation of 0.1% or 0.25% Dex within the scaffold was found to significantly accelerate islet engraftment in a diabetic mouse model, resulting in improved control of blood glucose levels during the early transplant period. Investigation into the mechanism of this impact found that local Dex delivery promotes macrophage polarization towards an anti-inflammatory (M2) phenotype and suppresses inflammatory pathways during the first week post-implantation. Alternatively, higher Dex loadings (0.5% and 1%) significantly delayed islet engraftment and function by impairing host cell migration into the implanted graft. Our results demonstrate the dose-dependent impact of local glucocorticoid delivery on the modulation of inflammatory responses at the implant site in vivo. Outcomes highlight the potential of this platform for generating favorable host responses that improve overall cellular transplant outcomes.

Introduction

Type 1 diabetes (T1D) is an autoimmune disease resulting in the targeted destruction of insulin-secreting beta cells. Clinical islet transplantation, where allogeneic pancreatic islets are infused into the portal vein of the liver, has achieved insulin independence for individuals suffering from labile diabetes with severe hypoglycemic unawareness [1]. Graft efficacy is unstable, however, as multiple transplant-related factors, such as poor engraftment and host inflammatory and immunological responses, result in the significant loss of islets [2]. In an effort to improve graft duration, our laboratory developed a three-dimensional macroporous polydimethylsiloxane (PDMS) scaffold for housing transplanted islets [3]. Placement of islet-loaded scaffolds within an extrahepatic site (i.e. the omentum) results in stable efficacy in syngeneic and allogeneic diabetic rodent and nonhuman primate models [4]. The highly interconnected and porous structure of the PDMS scaffold facilitates positive interactions between graft and host tissue, resulting in a supportive microenvironment [3]. Further, the localization of islets within a defined implant permits ease of monitoring and retrieval, as well as the integration of beneficial factors, such as proangiogenic hydrogels [5].

With the potential of this 3-D platform to locally instruct host responses to the islet graft, efforts were focused on decreasing inflammatory events instigated post-transplant. In clinical studies, inflammation has been implicated as a prominent player in decreasing islet viability and graft efficacy [6]. Activation of the inflammatory cascade starts early, whereby pro-inflammatory mediators, such as tissue factor and high-mobility group box-1 protein, are upregulated by stressed islets following pancreatic isolation. The transplantation of islets subsequently triggers thrombosis, complement cascade, and an instant blood-mediated inflammatory reaction (IBMIR), which results in early islet loss (∼60% of the islet mass) and the promotion of adaptive immune responses [7], [8]. When biomaterials are added to the transplant microenvironment, activation of inflammatory processes can be further amplified, due to foreign body responses (FBR) [9]. To mitigate inflammation in clinical islet transplantation, supplemental administration of TNFα and IL-1β blockers (etanercept and anakinra) has been shown to dampen pro-inflammatory effectors and lead to improved allograft survival [10]. The intravenous delivery of these agents, however, results in detrimental systemic impacts such as an increased risk of serious infections.

The engineering of a localized drug delivery platform could avoid the side effects of systemic anti-inflammatory regimens, while also precisely modulating inflammatory responses at the transplant site. An optimal drug and dosage would suppress active inflammatory pathways and instruct local host responses towards desirable phenotypes. Directing macrophage phenotype is of particular interest, as macrophages are key contributors in determining the overall outcome of the host response to an implant [11]. During normal activation and resolution of inflammatory processes, the macrophage population covers a balanced spectrum of phenotypes. On one end of this spectrum are classically activated macrophages (termed M1), which generate a microenvironment rich in reactive oxygen species, degradative enzymes, and pro-inflammatory cytokines (e.g. IL-1β, IL-6, and TNFα) [12]. On the other end are the alternatively activated subtype (termed M2) that is associated with a different portfolio of cytokines (e.g. IL-10 and TGFβ) that facilitate healthy tissue remodeling [13]. Local pro-inflammatory instigators and undesirable implants tip this balance towards M1, which can result in detrimental downstream events such as the generation of a fibrotic capsule, the promotion of detrimental Th1 responses, and the destruction of the graft [14]. Alternatively, modest promotion of the M2 phenotype has been shown to direct positive tissue remodeling, resulting in functional engraftment of the implant [15]. These M2 macrophages impart additional benefits to islet transplants, as they have been shown to promote islet function and beta cell proliferation [16].

A strong drug candidate for this approach is dexamethasone (Dex). Dex, an immunosuppressive glucocorticoid capable of potent suppression of inflammatory pathways, has been shown to polarize human blood-derived monocytes toward the anti-inflammatory (M2) phenotype, while retaining their migratory function [17], [18]. The Dex dosage must be carefully tailored, however, to prevent overloading at the implant site, as elevated glucocorticoids can severely impair cell mobility, resulting in compromised engraftment and vascularization [19]. Further, Dex has also been shown to impair the glucose responsiveness of beta cells at high concentrations [20]. In this study, we utilized our macroporous PMDS scaffold platform to locally deliver dexamethasone in a controlled manner within the desired therapeutic range (Fig. 1). This streamlined approach eliminated the need for disparate drug depots, as previously explored [21]. Evaluation of kinetic release of Dex from the 3-D scaffold permitted tailoring of drug loading to desired doses. Following optimization, the impact of this drug-release platform on the efficiency of islet engraftment and subsequent host cell responses were investigated.

Section snippets

Fabrication of Dex-PDMS scaffolds and characterization of Dex-releasing kinetics

Macroporous PDMS scaffolds of 85% total porosity were fabricated by particle leaching and solvent casting, as described previously [3]. In brief, the PDMS matrix was prepared by mixing PDMS part A with cross-linker part B (RTV 615 A/B kit, Momentive) at a ratio of 4:1 (A:B). Dexamethasone (Enzo life sciences) was subsequently added to the PDMS mixture at the desired percentage (1, 0.5, 0.25, and 0.1% weight-to-weight, which results in a total mass of 182, 90.5, 45.1, and 18 μg Dex per scaffold

Characterization of Dex release profiles from PDMS scaffolds

The macroporous PDMS scaffold serves as a supportive 3-D platform for housing islets following transplantation (Fig. 2A–C). For simplicity of engineering design, dexamethasone was incorporated directly into the PDMS liquid prior to the fabrication of the resulting scaffold. To ensure appropriate Dex release kinetics from the 3-D implant, varying concentrations of Dex (1.0, 0.5, 0.25, and 0.1% w/w) were screened. Despite the unpredictable surface area of the scaffold, drug release profiles were

Discussion

Biomaterial delivery systems are attractive platforms over direct daily injections, as they facilitate the localized delivery of therapeutic agents in a controllable fashion over extended time periods, while eliminating the complications of patient compliance. Via the manipulation of biomaterial characteristics (e.g. architecture, degradation, and drug loading), customized constructs can meet distinctive physiological demands. By incorporating Dex directly into the 3-D platform used to house

Conclusion

A Dex-PDMS scaffold provides a feasible platform to locally deliver immunomodulatory dexamethasone in a controllable manner and thereby foster a protective microenvironment for engrafted islets. In this study, we characterized the impact of Dex-PDMS scaffolds on modulating inflammatory response in the transplant milieu. The local, low-dose delivery of Dex via a macroporous scaffold demonstrated macrophage polarization towards an anti-inflammatory phenotype and significantly improved islet

Acknowledgements

This work was supported by a partnership grant from the JDRF and Leona M. and Harry B. Helmsley Charitable Trust (3-SRA-2015-38-Q-R) and the University of Florida Preeminence funding. We thank Irayme Labrada for her excellent technical assistant during animal transplants. We thank the Diabetes Research Institute Preclinical and Translational Models Core lab for providing the rodent islets used in this project. We thank Kevin Johnson from the Diabetes Research Institute for his consistent

References (43)

  • E. Pedraza et al.

    Synthesis of macroporous poly(dimethylsiloxane) scaffolds for tissue engineering applications

    J. Biomater. Sci. Polymer Ed.

    (2013)
  • E. Pedraza et al.

    Macroporous Three-dimensional PDMS scaffolds for extrahepatic islet transplantation

    Cell Transplant.

    (2013)
  • A.-C. Brady et al.

    Proangiogenic hydrogels within macroporous scaffolds enhance islet engraftment in an extrahepatic site

    Tissue Eng. Part A

    (2013)
  • A. Citro et al.

    Anti-Inflammatory strategies to enhance islet engraftment and survival

    Curr. Diab Rep.

    (2013)
  • N. Matsuoka et al.

    High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice

    J. Clin. Investig.

    (2010)
  • T. Eich et al.

    Positron emission tomography: a real-time tool to quantify early islet engraftment in a preclinical large animal model

    Transplantation

    (2007)
  • A. Sahraoui et al.

    Anakinra and tocilizumab enhance survival and function of human islets during culture: implications for clinical islet transplantation

    Cell Transplant.

    (2013)
  • D.M. Mosser et al.

    Exploring the full spectrum of macrophage activation

    Nat. Rev. Immunol.

    (2008)
  • F.O. Martinez et al.

    Alternative activation of macrophages: an immunologic functional perspective

    Annu. Rev. Immunol.

    (2009)
  • O. Veiseh et al.

    Size-and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates

    Nat. Mater.

    (2015)
  • X. Xiao et al.

    Concise review: new insights into the role of macrophages in beta-cell proliferation

    Stem Cells Transl. Med.

    (2015)
  • Cited by (0)

    View full text